Top Business News

EXTON, Pa., Apr 13 (UPI) -- The U.S. Defense Department is resource a Pennsylvania biopharmaceutical company to hold utilization of therapeutic antibodies against bio-warfare agents.

Morphotek, Inc., a subsidiary of Eisai Inc., said the grant to hold the continuing utilization of therapeutic monoclonal antibodies confident of neutralizing the cyanogenic effects of botulinum neurotoxins is worth most $947,000.

In 2007, Morphotek was awarded $2.3 meg in resource to hold the initial utilization of these mAb therapies.

"The (Defense Department) resource will earmark us to explore novel antibody formats confident of interference the cyanogenic effects of destined BOTN sub-types," said Luigi Grasso, Ph.D., honcho technological officer at Morphotek. "(The Defense Department's) resource for this information demonstrates the importance of developing non-animal derivative and innocuous biological therapies to impact possibleness danger to different weaponized BOTN subtypes."

The funded information is in salutation to polity efforts to amend therapies confident of protecting civilian and military organisation against danger to pathogenic agents that crapper be deployed by rapscallion states or terrorists as bio-weapons.

Morphotek specializes in the utilization of protein and antibody products finished the use of a novel and proprietary gene phylogenesis technology.